ANTIEPILEPTIC DRUGS MARKET ANALYSIS

Antiepileptic Drugs Market, By Generation (First Generation, Second Generation, Third Generation), By Route of Administration (Oral, Intravenous, Others (nasal, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Restraint: The key factor hindering the market growth is product recall. Product recall hampers the companies image in the market as well affect sales of other products in the same segment. According to the Government of U.K., on July 13, 2023, Sanofi, a U.K.based pharmaceutical company, recalled the listed batches of Sabril tablets and Sabril granules as a precautionary measure, due to the discovery of residues of tiapride in batches of the manufacturer's source material for vigabatrin. Sabril (vigabatrin) is approved as an additional treatment for focal seizures with or without subsequent generalization that have not been adequately managed with other anti-epileptics (under professional supervision) and as monotherapy for infantile spasms (West's syndrome).
Counterbalance: Key players operating in this market should adhere to good manufacturing practices (GMO), thus, decreasing the chances of unwanted residues in the final product.